Open AccessSafety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study
Author(s) -
Fadwa AlAli,
Ahmad Hamdy,
Abdullah Hamad,
Mohamed Elsayed,
Zafar Zafar Iqbal,
Aisha Elsayed,
Rania Ibrahim,
Hoda Tolba,
Hisham Buanan,
Ashraf Fawzy
Publication year - 2017
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfx187
Subject(s) - medicine , catheter , hemodialysis , dialysis catheter , urokinase , surgery , thrombosis , randomized controlled trial , heparin , dialysis , anesthesia
Taurolidine citrate with heparin (Taurolock/Hep) is a promising central venous catheter lock solution. Despite its universal use among our hemodialysis patients, the prevalence of catheter malfunction was high. We aimed to compare Taurolock/Hep and taurolidine citrate with urokinase (Taurolock/U) as a catheter lock solution in order to identify whether either solution could reduce catheter-related dysfunction.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom